home / stock / nbix / nbix quote
Last: | $142.29 |
---|---|
Change Percent: | -0.04% |
Open: | $141.97 |
Close: | $142.29 |
High: | $142.86 |
Low: | $140.51 |
Volume: | 641,937 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$142.29 | $141.97 | $142.29 | $142.86 | $140.51 | 641,937 | 05-17-2024 |
$141.91 | $141.17 | $141.91 | $142.3 | $140.17 | 670,978 | 05-16-2024 |
$142 | $138.9 | $142 | $142.19 | $138.9 | 684,685 | 05-15-2024 |
$138.48 | $137.12 | $138.48 | $138.73 | $134.79 | 622,237 | 05-14-2024 |
$136.15 | $138 | $136.15 | $138.685 | $135.23 | 712,827 | 05-13-2024 |
$136.7 | $140 | $136.7 | $140.9999 | $136.1 | 679,327 | 05-10-2024 |
$139.66 | $139.36 | $139.66 | $140.71 | $138.95 | 479,494 | 05-09-2024 |
$139.02 | $143.5 | $139.02 | $143.54 | $138.15 | 653,578 | 05-08-2024 |
$143.19 | $142.03 | $143.19 | $143.86 | $140.9 | 667,258 | 05-07-2024 |
$141.71 | $140.55 | $141.71 | $143.57 | $140.55 | 483,775 | 05-06-2024 |
$140.71 | $140.9 | $140.71 | $141.88 | $139.23 | 616,567 | 05-03-2024 |
$139.83 | $143.79 | $139.83 | $144.09 | $139.63 | 882,407 | 05-02-2024 |
$143.03 | $140.18 | $143.03 | $145.22 | $136.01 | 1,601,873 | 05-01-2024 |
$137.54 | $138.07 | $137.54 | $140.47 | $137.34 | 966,534 | 04-30-2024 |
$138.89 | $136.05 | $138.89 | $139.37 | $136.05 | 681,748 | 04-29-2024 |
$135.99 | $137.47 | $135.99 | $138.63 | $135.17 | 717,575 | 04-26-2024 |
$137.76 | $139.37 | $137.76 | $139.37 | $136.06 | 735,781 | 04-25-2024 |
$138.97 | $140.89 | $138.97 | $144.7 | $138.01 | 883,288 | 04-24-2024 |
$140.09 | $141 | $140.09 | $145 | $139.22 | 1,607,701 | 04-23-2024 |
$133.66 | $132.48 | $133.66 | $134.1798 | $131.7949 | 575,067 | 04-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024 PR Newswire - CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitatio...
2024-05-13 17:00:06 ET Cory Kasimov from Evercore ISI issued a price target of $175.00 for NBIX on 2024-05-13 16:13:00. The adjusted price target was set to $175.00. At the time of the announcement, NBIX was trading at $136.15. The overall price target consensus is at $1...
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024 PR Newswire CAHtalyst™ Study Baseline Characteristics Highlight the Need for New Treatment Options to Reduce...